LOS ANGELES, Sept. 07, 2017 -- Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against Vitamin Shoppe, Inc. (“Vitamin Shoppe” or the “Company”) (NYSE:VSI) concerning possible violations of federal securities laws between March 1, 2017 and August 6, 2017, inclusive (the “Class Period”). Investors who purchased or otherwise acquired shares during the Class Period should contact the firm prior to the October 27, 2017 lead plaintiff motion deadline.
To participate in this class action lawsuit, click here.
You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or you can e-mail him at [email protected].
No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.
According to the Complaint, throughout the Class Period, Vitamin Shoppe made false and/or misleading statements, and/or failed to disclose: that the Company’s retail segment was continuing to dramatically decline; that its ongoing “reinvention plan” had been unsuccessful and brought more than $168 million in goodwill impairment, and it was not properly recognizing that impairment charge; and that as a result of the above, the Company’s public statements were materially false and misleading at all relevant times. Upon release of this information, shares of Vitamin Shoppe fell in value materially, which caused investors harm according to the Complaint.
Lundin Law PC was founded by Brian Lundin, Esq., a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethics rules.
Contact: Lundin Law PC Brian Lundin, Esq. Telephone: 888-713-1033 Facsimile: 888-713-1125 [email protected] http://lundinlawpc.com/


Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore
Luxury Car Sales in the Middle East Take a Hit Amid Iran War
Brown-Forman and Pernod Ricard in Merger Talks to Create World's Largest Spirits Giant 



